Vicore Pharma Holding AB (publ) (VICO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.074x

Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has a cash flow conversion efficiency ratio of -0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-81.48 Million ≈ $-8.77 Million USD) by net assets (Skr1.10 Billion ≈ $117.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Vicore Pharma Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Vicore Pharma Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Vicore Pharma Holding AB (publ) for a breakdown of total debt and financial obligations.

Vicore Pharma Holding AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ningbo Xianfeng New Material SHE:300163	-0.038x
Pss Co Ltd TW:6914	0.236x
Vinacafe Bien Hoa JSC VN:VCF	-0.043x
SIMONA AG O.N. F:SIM0	N/A
Sword Group S.E PA:SWP	-0.158x
Advancetek Enterprise Co Ltd TW:1442	0.007x
CLINUVEL PHARMAC.ADRS1 F:UR9A	N/A
Trastor Real Estate Investment Company SA AT:TRASTOR	0.008x

Annual Cash Flow Conversion Efficiency for Vicore Pharma Holding AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Vicore Pharma Holding AB (publ) from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vicore Pharma Holding AB (publ).

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr1.10 Billion ≈ $117.89 Million	Skr-374.44 Million ≈ $-40.30 Million	-0.342x	-134.02%
2024-12-31	Skr1.13 Billion ≈ $121.53 Million	Skr-164.95 Million ≈ $-17.75 Million	-0.146x	+73.35%
2023-12-31	Skr455.39 Million ≈ $49.01 Million	Skr-249.58 Million ≈ $-26.86 Million	-0.548x	+47.17%
2022-12-31	Skr289.08 Million ≈ $31.11 Million	Skr-299.92 Million ≈ $-32.28 Million	-1.037x	-49.97%
2021-12-31	Skr383.32 Million ≈ $41.25 Million	Skr-265.17 Million ≈ $-28.54 Million	-0.692x	-104.48%
2020-12-31	Skr354.51 Million ≈ $38.15 Million	Skr-119.94 Million ≈ $-12.91 Million	-0.338x	-25.06%
2019-12-31	Skr321.60 Million ≈ $34.61 Million	Skr-87.00 Million ≈ $-9.36 Million	-0.271x	-133.73%
2018-12-31	Skr285.44 Million ≈ $30.72 Million	Skr-33.04 Million ≈ $-3.56 Million	-0.116x	-69.69%
2017-12-31	Skr112.97 Million ≈ $12.16 Million	Skr-7.71 Million ≈ $-829.18K	-0.068x	+28.89%
2016-12-31	Skr75.60 Million ≈ $8.14 Million	Skr-7.25 Million ≈ $-780.32K	-0.096x	-113.43%
2015-12-31	Skr81.93 Million ≈ $8.82 Million	Skr-3.68 Million ≈ $-396.24K	-0.045x	+14.58%
2014-12-31	Skr53.70 Million ≈ $5.78 Million	Skr-2.83 Million ≈ $-304.02K	-0.053x	-17.40%
2013-12-31	Skr40.01 Million ≈ $4.31 Million	Skr-1.79 Million ≈ $-192.96K	-0.045x	+29.52%
2012-12-31	Skr26.25K ≈ $2.82K	Skr-1.67K ≈ $-179.61	-0.064x	--

About Vicore Pharma Holding AB (publ)

ST:VICO Sweden Biotechnology

Market Cap

$302.36 Million

Skr2.81 Billion SEK

Market Cap Rank

#14932 Global

#234 in Sweden

Share Price

Skr9.98

Change (1 day)

-0.40%

52-Week Range

Skr7.35 - Skr13.34

All Time High

Skr37.60